Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Todua Clinic | Healthcare Services | 40.0% | 95th pct | 268 |
| New Hospitals | Healthcare Services | 17.1% | 72nd pct | 268 |
| Geo Hospitals | Healthcare Services | 8.8% | 47th pct | 268 |
| Georgian Hospitals Group | Healthcare Services | 8.8% | 46th pct | 268 |
| EVEX Hospitals | Healthcare Services | — | no FY data | 268 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.
Only 4 of 5 peers filed FY2024. Switch to FY2023 (5 of 5).
| Ratio — FY 2024 | Todua Clinic | New Hospitals | Geo Hospitals | Georgian Hospitals Group | EVEX Hospitals |
|---|---|---|---|---|---|
| Margins | |||||
| Gross Margin | 91.7% | 79.2% | 78.0% | 78.0% | — |
| EBITDA Margin | 40.0% | 17.1% | 8.8% | 8.8% | — |
| EBITDAR | 40,902 | 15,761 | 7,906 | 7,899 | — |
| EBITDAR Margin | 40.0% | 17.1% | 8.8% | 8.8% | — |
| EBIT Margin | 29.6% | 11.6% | 1.4% | 1.1% | — |
| Net Profit Margin | 29.2% | 11.8% | -4.9% | -5.3% | — |
| Operating Expense % of Sales | 52.8% | 62.2% | 70.1% | 70.1% | — |
| Returns | |||||
| Return on Assets (ROA) | 16.0% | 9.5% | -3.1% | -3.1% | — |
| Return on Equity (ROE) | 16.8% | 11.8% | -8.7% | -8.2% | — |
| ROIC [EBIT / Invested Capital] | |||||
| 17.7% |
| 10.6% |
| 1.0% |
| 0.7% |
| — |
| Leverage & debt balances | |||||
| Debt-to-Assets | 1.9% | 9.1% | 50.5% | 50.3% | — |
| Debt-to-Equity | 0.02x | 0.11x | 1.40x | 1.35x | — |
| Debt-to-EBITDA | 0.09x | 0.66x | 9.10x | 9.90x | — |
| Equity-to-Assets | 95.2% | 80.3% | 36.0% | 37.2% | — |
| Net Debt | -6,787 | 8,579 | 71,723 | 77,973 | — |
| Cash & Equivalents | 10,399 | 1,849 | 257 | 263 | — |
| Total Debt | 3,612 | 10,428 | 71,981 | 78,235 | — |
| Liquidity & working capital | |||||
| Current Ratio | 4.37x | 1.37x | 0.87x | 0.57x | — |
| Quick Ratio | 4.07x | 1.03x | 0.74x | 0.48x | — |
| Cash Ratio | 1.44x | 0.11x | 0.01x | 0.01x | — |
| Total Current Assets | 31,653 | 23,861 | 28,589 | 28,605 | — |
| Total Current Liabilities | 7,235 | 17,439 | 32,939 | 50,571 | — |
| Inventory | 2,184 | 5,921 | 4,115 | 4,115 | — |
| Trade Receivables | 16,635 | 15,403 | 17,383 | 17,383 | — |
| Trade Payables | 1,204 | 5,295 | 19,094 | 19,193 | — |
| Net Working Capital | 24,418 | 6,422 | -4,350 | -21,967 | — |
| Net Working Capital % of Revenue | 23.9% | 7.0% | -4.8% | -24.4% | — |
| Trade Working Capital | 17,615 | 16,029 | 2,403 | 2,305 | — |
| Trade Working Capital % of Revenue | 17.2% | 17.4% | 2.7% | 2.6% | — |
| Change in Trade Working Capital | N/A | N/A | N/A | N/A | — |
| Turnover & efficiency | |||||
| Inventory Turnover | 3.90x | 3.24x | 4.82x | 4.82x | — |
| Days Inventory Outstanding (DIO) | 93.5 | 112.7 | 75.7 | 75.7 | — |
| Receivables Turnover | 6.15x | 5.99x | 5.18x | 5.18x | — |
| Days Sales Outstanding (DSO) | 59.3 | 60.9 | 70.4 | 70.4 | — |
| Payables Turnover | 7.08x | 3.62x | 1.04x | 1.03x | — |
| Days Payable Outstanding (DPO) | 51.5 | 100.8 | 351.3 | 353.1 | — |
| Cash Conversion Cycle | 101.3 days | 72.8 days | -205.2 days | -207.0 days | — |
| Asset Turnover | 0.55x | 0.80x | 0.63x | 0.58x | — |
| Cash flow & dividends | |||||
| Operating Cash Flow | 38,019 | 11,773 | 11,251 | 11,246 | — |
| Free Cash Flow (OCF − Capex proxy) | 553 | 5,639 | -383 | -389 | — |
| Cash Conversion (OCF / EBITDA) | 93.0% | 74.7% | 142.3% | 142.4% | — |
| Dividends Declared | 2,474 | 0 | 0 | 0 | — |
| Dividend Payout Ratio | 8.3% | 0.0% | N/A | N/A | — |